MOMA Therapeutics is developing next-generation precision medicines focusing on ATPases implicated in disease. The Boston-based biopharmaceutical company is developing a platform to exploit a critical weakness shared by all ATPases: their reliance on well-coordinated, sequential changes in protein structure. GEN Edge sat down with MOMA CEO Asit Parikh, MD, PhD, to understand how MOMA is creating pharmaceuticals for a notoriously tricky enzyme class . . .